Cannabidiol Oral Solution: Challenges as a Treatment for Seizure Syndromes

•Cannabidiol oral solution (Epidiolex) is an effective adjunctive agent for treatment-resistant seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.•Doses of Epidiolex should be reduced for patients with significantly compromised liver function, and transaminase levels should be monitored.•Epidiolex is considered schedule V because oil or other derivatives or extracts made from cannabis seeds with a THC concentration of less than 0.3% are no longer as stringently controlled under the Controlled Substances Act.